A Placebo-controlled, Double-blind Evaluation of Safety, Tolerability, and Efficacy of XT- 150 for the Treatment of Facet Joint Osteoarthritis Pain
Latest Information Update: 17 Jan 2025
At a glance
- Drugs XT-150 (Primary)
- Indications Osteoarthritis; Pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors Xalud Therapeutics
Most Recent Events
- 24 Oct 2023 Status changed from active, no longer recruiting to completed.
- 19 Jan 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Sep 2023.
- 19 Jan 2023 Status changed from recruiting to active, no longer recruiting.